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ABStRACt. Osteogenesis imperfecta is a heterogeneous genetic 
disorder  characterized  by  bone  fragility  and  deformity,  recurrent 
fractures, blue sclera, short stature, and dentinogenesis imperfecta. Most 
cases are caused by mutations in COL1A1 and COL1A2 genes. We 
present a novel splicing mutation in the COL1A1 gene (c.1875+1G>C) 
in a 16-year-old Brazilian boy diagnosed as a type III osteogenesis 
imperfecta  patient.  This  splicing  mutation  and  its  association  with 
clinical  phenotypes  will  be  submitted  to  the  reference  database  of 174
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COL1A1 mutations, which has no other description of this mutation. 
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INtRODuCtION
Osteogenesis imperfecta (OI) is a heterogeneous genetic disorder characterized 
by bone fragility and deformity, recurrent fractures, blue sclera, short stature, and denti-
nogenesis imperfecta. Based on clinical and radiological findings, OI is traditionally sub-
classified as type I (mild), II (lethal), III (severe), and IV (moderate), but recent classifica-
tions include types V, VI and VII, based on histological and radiological aspects (Sillence 
et al., 1979; Glorieux et al., 2000, 2002; Ward et al., 2002; Barnes et al., 2006). 
Most cases are caused by mutations with dominant inheritance in COL1A1 and 
COL1A2 genes, which code for type I collagen chains, an important structural protein 
of bone, cartilage and tendons (Barsh and Byers, 1981; Gajko-Galicka, 2002; Marini et 
al., 2007). However, there are rare cases of recessive OI associated with mutations in the 
CRTAP and LEPRE1 genes (Morello et al., 2006; Cabral et al., 2007). 
In general, mutations in COL1A1 and COL1A2 genes cause quantitative or qualita-
tive defects, associated with mild and severe forms of OI, respectively (Redford-Badwal et 
al., 1996; Forlino and Marini, 2000). Nonetheless, the genotype/phenotype correlation is not 
completely established and molecular studies associated with clinical investigations are neces-
sary to better understand the genetic aspects of OI. 
We present a novel mutation in the COL1A1 gene of a proband diagnosed as a type III 
OI patient, the most severe non-lethal form of OI.
SuBJeCt AND MethODS
This study was approved without restrictions by the Research Ethics Committee of the 
Hospital Infantil Nossa Senhora da Glória, and authorized by the patient’s mother.
Clinical report
The patient is a 16-year-old Brazilian boy diagnosed with type III OI (severe), based 
on clinical aspects. He is one of two sons of a non-consanguineous couple, and he is the only 
diagnosed case in his family. At birth, he had several fractures and at the time of the study, he 
had suffered over 100 fractures. Currently, the patient is approximately 121 cm tall and weighs 
32 kg. His head circumference is 60 cm, which is below the 2.5% percentile. The fractures have 
decreased and he does not have intramedullary rods. However, the limbs are seriously deformed 
and he has needed a wheelchair for mobility since 8 years old. Hearing is normal, but the patient 
has a blue sclera and myopia. He has dentinogenesis imperfecta and osteopenia. The radiographs 
show a rectification of the thoracolumbar spinal column and the attenuation of the kyphosis and 
lordosis. The changes in bone mineral density of the lumbar spine (L1-L4) and total body during 
the treatment with pamidronate can be seen in Figures 1 and 2. The patient has been treated with 
pamidronate since he was 11 years old.175
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Figure 1. Bone mineral density, BMD (total body) in g/cm2 during treatment with pamidronate.
Figure 2. Bone mineral density, BMD (lumbar spine L1-L4) in g/cm2 during treatment with pamidronate.
Molecular analysis
The proband’s DNA, as well as DNA of his mother and one hundred unaffected in-
dividuals of the same population, were extracted from peripheral blood cells (Miller et al., 
1988). It was not possible to analyze the proband’s father’s DNA because he was deceased. 
Fragments containing the exons of the COL1A1 gene were amplified in an Applied Biosystems 
GeneAmp®PCR System 9700 model using primers described by Körkkö et al. (1998). Poly-176
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merase chain reaction products were screened for mutations by single-stranded conformation 
polymorphism, on 5% polyacrylamide-5% glycerol gels and on 6% glycerol MDE (Cambrex 
Bio Science Rockland, Inc.) gels (Orita et al., 1989; Spinardi et al., 1991). Fragments showing 
abnormal migration pattern were sequenced to detect variation in the DNA sequences, which 
were subsequently compared with mutations described in the Osteogenesis Imperfecta Muta-
tion Database (Dalgleish, 2008) and whose reference sequence is Z74615 (NCBI, 2008).
ReSuLtS 
Molecular screening showed abnormal migration patterns for fragments containing 
exons 27 (Figure 3), 30, 31, 44, and 45. Control samples also showed the same abnormal pat-
terns for exons 30, 31, 44, and 45, but not for exon 27. Therefore, exon 27 of the proband’s 
mother was also analyzed and found to show a normal migration pattern. 
Figure 3. Molecular analysis of the proband’s fragment containing exon 27. A. Single-stranded conformational 
polymorphism analysis showing abnormal migration pattern for the proband (P) when compared with the proband’s 
mother (M) and a control (C) sample. B. Sequencing of the abnormal fragment resulting in the identification of a 
guanine to cytosine substitution in intron 27 (c.1875+1G>C). 
Sequencing of the abnormal fragments of the patient resulted in the identification of 
five different nucleotide substitutions (Table 1).
Substitution  Location  Variation  Allelic frequency in
     100 control samples
c.1875+1G>C  Intron 27  Splicing mutation  0.00
c.1984-41A>G  Intron 29  Polymorphism  0.08
c.2028+39T>C  Intron 30  Polymorphism  0.13
c.3208-32C>A  Intron 44  Polymorphism  0.05
c.3261+31C>T  Intron 45  Polymorphism  0.10
table 1. Allelic frequency of the COL1A1 nucleotide substitutions detected in the osteogenesis imperfecta patient. 
DISCuSSION 
The most notable genetic variation was the substitution of a guanine for a cytosine in 
the first nucleotide immediately after exon 27, in the splicing site of intron 27 of the patient 
with type III OI. 177
©FUNPEC-RP www.funpecrp.com.br Genetics and Molecular Research 8 (1): 173-178 (2009)
A novel COL1A1 gene splicing mutation
Precision in the splicing process is guided by conserved sequences at the 5’ and 3’ends 
of all introns. Dinucleotides GT (on the 5’ end) and AG (on the 3’ end) on the ends of the in-
trons are needed for correct splicing, and variations in these nucleotides could interfere with 
the normal synthesis of mRNA (Schwarze et al., 1999). The proband showed a variation in 
the intron 27 5’-dinucleotide of the COL1A1 gene. We suggest that the guanine to cytosine 
substitution in one of the intron 27 conserved regions interfered with normal splicing and the 
mutant intron was not precisely removed, causing OI.
Because the proband’s parents were not diagnosed as OI patients and his mother’s DNA 
did not show the mutation c.1875+1G>C, we also suggest that this is a de novo mutation case.
The splicing mutation described in this report and its association with clinical pheno-
types will be submitted to the reference database of COL1A1 mutations, which has no other 
description of the mutation reported here (Dalgleish, 2008).
Four of the five variations described here were detected in the patient and in con-
trol samples as well, characterizing polymorphic sites. The c.1984-41A>G, c.2028+39T>C, 
c.3208-32C>A, and c.3261+31C>T substitutions were found in a relatively high number of 
control samples. We also observed that these variations were single nucleotide substitutions in 
introns, not resulting in amino acid changes. Thus, because of the frequency in control samples 
and the location of the variations in the COL1A1 gene (introns 29, 30, 44, and 45), we suggest 
that these are non-pathogenic polymorphisms.
In conclusion, we detected four COL1A1 gene non-pathogenic polymorphisms and a 
novel splicing mutation (c.1875+1G>C) associated with type III OI. The genotype/phenotype 
correlation described here provides new information about the genetic aspects of OI.
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